Mycomagic Biotechnology Co., Ltd.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Dec 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 20, 2027The maintenance fee for Truncated glyceraldehyde-3-phosphate dehydrogenase promoter (US 9,163,250) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,759,100 | Carboxin resistance gene for Flammulina velutipes In force · From the USPTO record | In force | From the USPTO record | |
| US 7,973,215 | Method for the introduction of a heterologous polynucleotide into a mushroom In force · From the USPTO record | In force | From the USPTO record | |
| US 7,777,021 | Gylceraldehyde-3-phosphate dehydrogenase promoter and heterologous gene expression In force · From the USPTO record | In force | From the USPTO record | |
| US 9,163,250 | Truncated glyceraldehyde-3-phosphate dehydrogenase promoter In force · From the USPTO record | In force | From the USPTO record | |
| US 9,827,288 | Method for treating a refractory or relapsed lung cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 9,975,931 | Use of an immunomodulatory protein from Ganoderma in promoting neurite outgrowth In force · From the USPTO record | In force | From the USPTO record | |
| US 9,937,226 | Use of immunomodulatory protein from ganoderma in inhibiting cancer stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 11,058,746 | Use of immunomodulatory protein from Ganoderma in inhibiting fibrosis In force · From the USPTO record | In force | From the USPTO record | |
| US 11,077,168 | Use of an immunomodulatory protein in reducing damage caused by fine particulate matter In force · From the USPTO record | In force | From the USPTO record | |
| US 11,141,458 | Composition and methods for promoting and treating chronic wound healing In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 12: 3 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending